Autoimmune Disorders
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.
Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.